Please login to the form below

Not currently logged in
Email:
Password:

canakinumab

This page shows the latest canakinumab news and features for those working in and with pharma, biotech and healthcare.

Novartis in-licenses Akcea’s novel cardiovascular therapy

Novartis in-licenses Akcea’s novel cardiovascular therapy

The difficulty of developing and commercialising new cardiovascular treatments has been illustrated by two other Novartis drugs  - Entresto and canakinumab. ... The new development deal could help plug a gap left by canakinumab in its late-stage CVD

Latest news

More from news
Approximately 3 fully matching, plus 10 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics